ISPC - Cancer Breakthroughs, Blockchain Bets, and Biotech Boldness

2025-09-05 09:27:48 ET

DENVER, Colo., Sep 05, 2025 ( 247marketnews.com )- LIXTE (NASDAQ:LIXT) headlines the morning buzz as it continues to position its lead compound, LB-100 , as a transformational player in oncology. LB-100 is the world’s only clinical-stage inhibitor of protein phosphatase 2A (PP2A) , a regulatory enzyme exploited by cancer cells to survive traditional therapies.

Described as a “cancer power-up” , LB-100 doesn’t just kill tumor cells, it forces them into “lethal activation,” enhances visibility to the immune system, and supercharges chemo, immunotherapy, and radiation . Currently, the compound is being evaluated in trials for:

• Ovarian clear-cell carcinoma [in collaboration with GlaxoSmithKline plc (NYSE:GSK)] ,
• MSS colorectal cancer [with Roche Holding AG (OTCQX:RHHBY) ], though enrollment is temporarily paused,
• And previously in soft-tissue sarcoma , where Phase 1 showed favorable safety, though the focus is shifting to higher-potential indications.

Roche Holding AG (SIX:RO)(OTCQX:RHHBY) continues its diagnostic dominance with CE IVDR approval for two key expansions of its VENTANA HER2 (4B5) assay. The update marks a leap forward in two high-need indications:

• HER2-ultralow metastatic breast cancer , where ENHERTU [by Daiichi Sankyo and AstraZeneca (NASDAQ:AZN)] offers new hope,
• And HER2-positive biliary tract cancer , enabling access to ZIIHERA (Jazz Pharmaceuticals’ zanidatamab-hrii).

“This is about creating new options for patients facing some of the toughest cancers,” said Roche Diagnostics’ Jill German , emphasizing Roche’s goal of precision treatment through cutting-edge diagnostics .

Notably, the DESTINY-Breast06 trial underpins the test’s value, showing significantly improved progression-free survival with ENHERTU in HER2-low and ultralow patients. Roche’s diagnostics arm continues to lead the charge toward individualized therapy access across Europe.

iSpecimen (NASDAQ:ISPC) is breaking out of biotech’s traditional mold and into blockchain . The biospecimen marketplace is building a $200 million digital asset treasury centered around Solana (SOL) , aiming to diversify its balance sheet and support long-term initiatives .

CEO Robert Lim stated that while the company is interested in “Locked SOL,” it’s also exploring a mix of liquid staking, tokenized assets, and selective spot trading . ISPC is in discussions with several crypto firms and plans to purchase SOL (locked and unlocked) via OTC transactions, pending legal and compliance vetting.

Meanwhile, iSpecimen closed a $1.75 million private placement to fund marketing and general operations. The company issued 1.56 million shares at $1.122 each , signaling confidence in its hybrid biotech-blockchain growth thesis.

Palisade Bio (NASDAQ:PALI) gained regulatory momentum after receiving a No Objection Letter from Health Canada for its Phase 1b trial of PALI-2108 , the first dual anti-inflammatory and anti-fibrotic therapy for fibrostenotic Crohn’s disease (FSCD) , a condition affecting up to half of Crohn’s patients and currently without approved antifibrotic treatment.

Phase 1b will assess safety, pharmacokinetics, and pharmacodynamics across 6–12 patients. Top-line data are expected in Q1 2026 , with Phase 2 IND submissions to the FDA planned shortly thereafter. CMO Dr. Mitchell Jones highlighted PALI-2108’s potential to go “beyond symptom management to alter the course of FSCD.”

Please go to https://247marketnews.com/lixte-biotechnology/ for further LIXT information and 247marketnews.com LIXT disclosure information.

The post Cancer Breakthroughs, Blockchain Bets, and Biotech Boldness appeared first on 24/7 MarketNews .

For further details see: